School of Medicine
Showing 171-174 of 174 Results
-
Muharrem Yunce, M.D.
Clinical Associate Professor, Pathology
BioDr. Yunce completed his transfusion medicine fellowship at Stanford and then gained invaluable clinical experience with the Malignant Hematology Group at UCSF for two years. After rejoining Stanford, Dr. Yunce started as the Medical Director of Therapeutic Apheresis. In this role, he works with clinicians from various departments, fellows, residents, and nursing staff to ensure life-saving and emergent procedures such as therapeutic plasma exchange (TPE), red cell exchange, plateletpheresis, and leukapheresis are conducted effectively. Additionally, Dr. Yunce oversees extracorporeal photopheresis for solid organ transplant rejection.
Dr. Yunce has been recognized for his contribution to the Department of Pathology as a faculty member in teaching and mentorship.He was selected for Teaching Award in 2023 and Mentor Award by the department and was nominated in 2023 and 2024 for the prestigious Alwin C. Rambar-James B.D. Mark Award for Excellence in Patient Care.
As an active member of the American Society of Apheresis, Dr. Yunce chairs the research subcommittee on TPE utilization in solid organ transplant rejection and desensitization protocols as well as he is member of multiple research subcommittees. -
James L. Zehnder, M.D.
Professor of Pathology (Research) and of Medicine (Hematology)
Current Research and Scholarly InterestsMy main research and clinical interests include molecular pathogenesis of acquired cytopenias, genetic testing for inherited non-malignant hematologic disorders, next-generation sequencing approaches to T and B cell clonality testing, somatic mutations in cancer and assessment of minimal residual disease in cancer patients.
-
Bing Melody Zhang
Clinical Associate Professor, Pathology
Current Research and Scholarly InterestsMy main research interests lie in the following areas:
1) HLA testing for BMT/solid organ transplantation
2) NGS-based TCR/Ig clonality/MRD testing
3) HLA testing in cellular therapy and oncology
4) Genetic/genomic testing for malignant and non-malignant hematologic disorders
5) HLA-related disease association/drug hypersensitivity testing.
